Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Libtayo
Marketing
Docs ask pharma for more NSCLC drugs, resources and research
Oncologists want more therapies, more resources for managing patients of color and more research into managing comorbidities.
Nick Paul Taylor
Jan 25, 2024 6:30am
Regeneron passes some European Libtayo rights to Medison Pharma
Jan 8, 2024 3:47pm
Regeneron's Libtayo delivers lung cancer win with BMS' Yervoy
Dec 1, 2022 12:25pm
Regeneron's Libtayo finally scores Keytruda-matching NSCLC nod
Nov 9, 2022 9:15am
Atara's first-in-class allogeneic T-cell therapy nears EU nod
Oct 14, 2022 11:18am
Regeneron expects approval delay of Libtayo plus chemo in NSCLC
Aug 3, 2022 12:35pm